Organon R&D Finland (formerly Forendo Pharma) is a drug development company focusing on novel treatments in women's health. Its pipeline includes HSD17B1 inhibitor, FOR-6219 for the treatment of endometriosis; dual HSD inhibitors for the treatment of broader gynecological conditions; and Fispemifene, a novel SERM for the treatment of male urological conditions.